ECOR electroCore

electroCore to Announce First Quarter March 31, 2025 Financial Results on Wednesday, May 7, 2025

electroCore to Announce First Quarter March 31, 2025 Financial Results on Wednesday, May 7, 2025

ROCKAWAY, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic technology company, announced today that it will report financial results for the first quarter ended March 31, 2025, after the close of the market on Wednesday, May 7, 2025.

Management will host a webinar at 4:30 PM EST to review the financial results and answer questions. Investors can access the webinar using the details below:

Wednesday, May 7, 4:30 PM EST

Dial-In: (646) 931-3860

Webinar ID: 885 4355 1292

Passcode: 419231

Registration Link: to participate and ask questions on the call.

About electroCore, Inc.

electroCore, Inc. and its subsidiaries (“electroCore” or the “Company”) is a commercial stage bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies.

For more information, visit .

Contact

ECOR Investor Relations

(973) 302-9253



EN
30/04/2025

Underlying

ECORelectroCore

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on electroCore

 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore Announces First Quarter 2025 Financial Results

electroCore Announces First Quarter 2025 Financial Results First quarter 2025 net sales of $6.7 million, an increase of 23% over first quarter 2024 Closed the acquisition of NeuroMetrix, Inc. (“NeuroMetrix”); first quarter 2025 unaudited Quell net sales of approximately $170,000  Company to host a conference call and webcast today, May 7, 2025 at 4:30 PM EDT ROCKAWAY, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a commercial-stage bioelectronic technology company, today announced financial results for the first quarter ended ...

May 7, 2025 1 EN
 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore Completes Acquisition of NeuroMetrix, Gaining Access to it...

electroCore Completes Acquisition of NeuroMetrix, Gaining Access to its Quell Platform, Creating Significant Player in Non-Invasive Bioelectronic Technologies Addition of Quell® Platform Broadens electroCore’s Bioelectronic Technology Portfolio and Accelerates Growth in Chronic Pain and Wellness Markets ROCKAWAY, N.J., May 02, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (“ECOR,” “electroCore,” or the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic technology company, announced today the completion of the merger (the “Merger”) with NeuroMetrix, Inc. (“NeuroMetrix” or “NURO”) (...

May 2, 2025 1 EN
 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore’s Truvaga™ Now Works with the Apple Health app

electroCore’s Truvaga™ Now Works with the Apple Health app ROCKAWAY, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that its flagship wellness product, Truvaga Plus, now works with the Apple® Health app. Truvaga Plus is a hand-held vagus nerve stimulator designed to elevate the day-to-day experience through quick and gentle activation of your vagus nerve. The product is designed to provide stress relief, improve sleep, enhance peace of mind and improve focus. Danielle Jones, Sr. Dir...

May 1, 2025 1 EN
 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore to Announce First Quarter March 31, 2025 Financial Results...

electroCore to Announce First Quarter March 31, 2025 Financial Results on Wednesday, May 7, 2025 ROCKAWAY, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic technology company, announced today that it will report financial results for the first quarter ended March 31, 2025, after the close of the market on Wednesday, May 7, 2025. Management will host a webinar at 4:30 PM EST to review the financial results and answer questions. Investors can access the webinar using the details below: Wednesday, May 7, 4:30 PM ESTDial-In: (646) 9...

April 30, 2025 1 EN
 PRESS RELEASE
Free
ECOR ELECTROCORE

gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Shown to be Effe...

gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Shown to be Effective in Treating Concussive Symptoms Associated with Mild Traumatic Brain Injuries ROCKAWAY, N.J., April 17, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that new data presented at the 2025 International Brain Injury Association World Congress highlights the effectiveness of gammaCore® non-invasive vagus nerve stimulation (nVNS) in treating concussive symptoms associated with mild traumatic brain injury (mTBI). Dr. Michael Am...

April 17, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch